Afamelanotide and Moles: How Melanocortins Alter Nevi in Skin Checks
When patients receive melanocortin therapies, changes in skin pigmentation can make routine dermatologic monitoring more complex. A primary concern during clinical skin examinations is whether these therapies trigger new growths or induce structural shifts in existing moles that mimic malignancy. In a 2021 study published in Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, researchers tracked the clinical and dermoscopic features of acquired melanocytic nevi to determine precisely how these spots respond to targeted melanocortin activation.
Why do clinicians monitor moles during melanocortin therapies?
Afamelanotide is a synthetic analogue of α-melanocyte-stimulating hormone that is clinically approved for patients affected by erythropoietic protoporphyria (EPP). Because the compound stimulates melanin production, it produces a "sun free" tanning response across the skin. However, treatment is also known to induce alterations in acquired melanocytic nevi (AMN) that are generically described as "darkening."
For dermatologists and patients, generalized darkening can raise concerns during routine full-body skin checks. Unregulated melanotan compounds sold online often lead people to wonder about pigment changes, but medical evaluations require precise surface microscopy to differentiate normal physiologic darkening from concerning atypical architecture. Understanding how approved peptide analogs alter existing moles helps clarify what clinicians observe under dermoscopy, as explored in discussions regarding Afamelanotide (Scenesse): The Approved Melanotan Relative.
How was the 2021 afamelanotide mole examination conducted?
To analyze these tissue responses systematically, the 2021 afamelanotide nevi study evaluated adult EPP patients who were treated with two afamelanotide implants administered 50 days apart. Clinicians enrolled adult patients and monitored a total of 103 acquired melanocytic nevi across multiple scheduled intervals.
Each patient underwent comprehensive clinical examinations and dermoscopic imaging at three specific checkpoints:
- Baseline (T0): Full-body documentation before receiving the first afamelanotide implant.
- Five Months (T1): Mid-term dermoscopic re-evaluation following the two doses.
- Twelve Months (T2): Long-term follow-up to evaluate whether observed tissue changes persisted or resolved.
During each review, investigators evaluated specific structural characteristics, including general pattern, symmetry, the number and size of pigmented globules, the morphology of the pigment network, and the potential appearance of any dermoscopic melanoma features.
What dermoscopic changes occurred under surface microscopy?
The examination revealed that afamelanotide alters the pigment architecture of existing moles, but these shifts follow a distinct, temporary timeline rather than permanent disorganization:
- Pigment network thickening: At 5 months (T1), all reticular nevi and 2-component acquired melanocytic nevi demonstrated focal network thickening.
- Reversibility at one year: By 12 months (T2), the focal network thickening had resolved entirely, returning to baseline status.
- Globule counts: An increase in the number of pigmented globules was observed at 5 months (T1), but this increase was no longer present at 12 months (T2).
- Patient variables: Statistical analysis showed that differences in globule counts were not influenced by the age or phototype of the patient.
These findings demonstrate that while therapeutic melanocortin receptor stimulation temporarily darkens the mole and accentuates reticular lines and globules, the underlying architecture does not undergo permanent distortion.
Did the study find any signs of malignant transformation?
A central question for patients researching melanocortin peptides is whether synthetic analogs cause moles to turn cancerous or spark sudden eruptions of new spots. In this trial, dermoscopic changes suggestive of malignancy were never seen across the 103 tracked lesions. Furthermore, the development of new acquired melanocytic nevi was never registered during the 12 months of monitoring.
The authors concluded that afamelanotide induces reversible changes in dermoscopic morphology without any signs of malignant transformation, and it does not stimulate the emergence of new moles. This provides useful perspective for individuals tracking mole changes, which is also addressed in reviews of Melanotan, Moles and Melanoma: What Case Reports Show.
What are the design limits of this single clinical evaluation?
While the findings provide valuable insight, readers must keep the design and boundaries of this research in mind:
- Single-study evidence: This was one specific prospective investigation examining adult patients with erythropoietic protoporphyria; it cannot represent every clinical scenario.
- Regulated versus illicit peptides: The subjects received pharmaceutical-grade afamelanotide in a strictly controlled medical setting with two controlled implants spaced 50 days apart. These outcomes cannot be applied to unregulated melanotan I or melanotan II products bought from illicit online vendors, which lack quality oversight, standardized dosing, and medical monitoring.
- Small sample size: The trial followed 103 nevi in a defined group of patients, which limits broad statistical power across diverse medical backgrounds.
Anyone noticing changes in the size, shape, color, or symmetry of a mole should always consult a board-certified dermatologist for a professional evaluation rather than relying on generalized trial outcomes.
Sources
- Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide. — PubMed / Photochemical & photobiological sciences (2021)
Published October 31, 2026. Sources are linked in the text. See our Medical Disclaimer.